Nevertheless, JQ1 monotherapy led to minimal or moderate delay in tumor growth, but combination treatment with eitherHDACs inhibitor Ricolinostat (138) or anti-PD-1 immunotherapy (139) significantly delayed tumor growth and improved survival of KP mice. Here, PDCD1 is linked to neoplasm.